One explanation for the global variations in PCa incidence is differences in the use of serum prostate-specific antigen (PSA) testing, which detects a glycoprotein that is normally expressed by prostate tissue and is elevated in most PCa types (1, 3–5). Here, KLK3 is linked to posterior cortical atrophy.